Grant: Catalyst Grant: Post Market Drug Safety and Effectiveness
University of Toronto
$49,924.00
Min(d)ing the Gap: Toward an Ethics Framework for Post-Market Surveillance of Prescription Drugs in Underrepresented Populations
EF 2011-12
Résumé
The underrepresentation and exclusion of women, children, older people, First Nations, Metis and Inuit peoples in clinical trials necessitates post-market surveillance of efficacy and safety in these populations. However, the biological risk and social vulnerability of these groups that in part justifies their exclusion from clinical trials also poses ethical issues in terms of their participation in surveillance activities. In addition, issues of equity in access, and social justice require that any ethical reflection be contextualized in the social and regulatory context in which research takes place. Through a comprehensive review of the ethics literature and subsequent qualitative content analysis, and through two case-studies, a preliminary ethics framework to guide research and regulation in post-market surveillance will be developed. Further areas for research and opportunities for engagement with key stakeholders will also be identified.
Programme
Catalyst Grant: Post Market Drug Safety and Effectiveness
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
244026
Name
Thompson Alison K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Catalyst Grant: Post Market Drug Safety and Effectiveness
Projecttitle
Min(d)ing the Gap: Toward an Ethics Framework for Post-Market Surveillance of Prescription Drugs in Underrepresented Populations
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$49,924
Cihrequipment2
$0
Programname2
Catalyst Grant: Post Market Drug Safety and Effectiveness
Keyworddelim
Bioethics; Marginalized Groups; Post-Market Surveillance; Prescription Drugs; Public Health Ethics
Abstract
The underrepresentation and exclusion of women, children, older people, First Nations, Metis and Inuit peoples in clinical trials necessitates post-market surveillance of efficacy and safety in these populations. However, the biological risk and social vulnerability of these groups that in part justifies their exclusion from clinical trials also poses ethical issues in terms of their participation in surveillance activities. In addition, issues of equity in access, and social justice require that any ethical reflection be contextualized in the social and regulatory context in which research takes place. Through a comprehensive review of the ethics literature and subsequent qualitative content analysis, and through two case-studies, a preliminary ethics framework to guide research and regulation in post-market surveillance will be developed. Further areas for research and opportunities for engagement with key stakeholders will also be identified.
Competitiondate
201110
Approvedterm2
1 yr 0 mth
Pinamesdelim
Thompson, Alison K
Approvedterm
1 an 0 mois
Cihrcontribution2
Ethics Office~ $49,924~ $0~